New hope for HIV patients who failed long-acting shots: switching to a daily pill
NCT ID NCT07620652
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether switching to a daily pill containing bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) can help people with HIV who previously did not respond to a long-acting injectable treatment (CAB/RPV LAI). The study includes 30 adults and will check if the switch leads to undetectable virus levels at 24 and 48 weeks. It also monitors safety and immune system changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)
What this could lead to
If successful, this could offer a new treatment option for people with HIV who have not responded to a specific long-acting injectable regimen.
What could go wrong
This is a small pilot study with only 30 participants, so results may not apply to everyone. The treatment may not work for those with certain drug resistance mutations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AOU Modena
Modena, MO, 41124, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••